]>
IRCT20091012002576N34 IRCT 2023-10-06 Tehran University of Medical Sciences Effect of Gh on pregnancy outcome in RIF Evaluation the effect of growth hormone (Gh) on pregnancy outcome of recurrent implantation failure (RIF) via intrauterine infusion. 2023-10-12 anticipated 60 Complete https://irct.ir/trial/72300 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: At First 30 letters A and 30 letters B are written on special papers that are not marked inside. Then all of them are placed in a bag and for each patient, after obtaining informed consent, a paper is removed randomly and without replacement, and based on the letter written on it, the desired intervention is performed for the patients. In addition, interventions A (case group) or B (control group) are determined by a lot, Blinding description: The evaluator physician differs from the care provider and analyzer only sees the codes in data sheet and are blinded regarding the groups but patients and care provider(who will done randomization) are not blinded. 2-3 Infertility. Intervention 1: Intervention group: for thirthy patients, intracavitary growth hormone will be injected by IUI ‌(Intrauterine Insemination) catheter one cm above internal OS cervix, 0.5 cc of Gh(Cinatrop Pen, cinagen company) at the 6th day of esterogen replacement therapy,after transvaginal sonogram. Intervention 2: Control group:At the sixth day of estrogen therapy at 30 patients,vaginal sonogram for evaluating endometrial thickness will be performed and estrogen will be continued. Yes - There is a plan to make this available What will be shared: Data of primary and secondary outcomes When: After publishing article To whom: To researchers of this filed Conditions: Writing in the reference list Where to obtain: By email How to obtain: Request by mail Comments:
public Fatemeh Davari Tanha
Yas hospital, North Nejatollahi Avenue, Karim khan Zand Bridge, Villa Street
Tehran Iran (Islamic Republic of) 159781597815 +98 21 8880 0115 Fatedavtanha@gmail.com Tehran University of Medical Sciences scientific Fatemeh Davari Tanha
North Nejatollahi Avenue, Karim khan Zand Bridge, Villa Street
Tehran Iran (Islamic Republic of) 159781597815 +98 21 8880 0115 Fatedavtanha@gmail.com Tehran University of Medical Sciences Iran (Islamic Republic of) History of recurrent implantation failure due to unknown etiology Having good quality mbryo 20 years 45 years Female User of corticosteroids User of glucose control agents CNS tumors Uterine malformations Asherman syndrome Cavity distorting lesions Severe endometriosis Liver disease Severe male infertility Body mass index(BMI)>30 Uncontrolled hypothyroidism N97.8 Female infertility of other origin Treatment - Drugs Treatment - Drugs Intervention group: for thirthy patients, intracavitary growth hormone will be injected by IUI ‌(Intrauterine Insemination) catheter one cm above internal OS cervix, 0.5 cc of Gh(Cinatrop Pen, cinagen company) at the 6th day of esterogen replacement therapy,after transvaginal sonogram. Control group:At the sixth day of estrogen therapy at 30 patients,vaginal sonogram for evaluating endometrial thickness will be performed and estrogen will be continued. Biochemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Beta HCG titer test (blood test). Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Heart beat activity by transvaginal sonogram. Tehran University of Medical Sciences Approved 2023-08-26 Ethic committee of Tehran University of medical sciences Sixth floor of central building of Tehran University of medical sciences, Ghods Avenue, Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)